Please login to the form below

Not currently logged in
Email:
Password:

hepatocellular carcinoma

This page shows the latest hepatocellular carcinoma news and features for those working in and with pharma, biotech and healthcare.

Liver cancer failure dents Opdivo potential by $1bn, says analyst

Liver cancer failure dents Opdivo potential by $1bn, says analyst

The failure of Opdivo to show efficacy in first-line hepatocellular carcinoma (HCC) – the most common form of liver cancer – isn’t a complete surprise as this form of cancer has ... patients. William Blair points to a number of upcoming trials in

Latest news

More from news
Approximately 1 fully matching, plus 46 partially matching documents found.

Latest Intelligence

  • Making Europe a leader in bioscience: boosting trust and opening minds Making Europe a leader in bioscience: boosting trust and opening minds

    This public-private research alliance is aimed at improving survival rates in hepatocellular carcinoma (the primary cancer of the liver).

  • Chinese biotech’s global ambitions Chinese biotech’s global ambitions

    Tislelizumab is in global phase III trials in a number of tumour types, including non-small cell lung cancer, hepatocellular carcinoma and oesophageal squamous cell carcinoma. ... It’s also in phase II trials in patients with previously treated

  • Deal Watch March 2016 Deal Watch March 2016

    Collaboration – discovery, development &commercialisation. $965. Exelixis/ Ipsen. Cabozantinib (Renal Cell Carcinoma, Hepatocellular Carcinoma, other indications) and Cometriq (medullary thyroid cancer).

  • Medius Deal Watch table for April 2015 Medius Deal Watch table for April 2015

    120. 4SC AG/Menarini. Licensing and development agreement. Resminostat (oral HDAC) for hepatocellular carcinoma.

  • Pharma deals in April 2015 Pharma deals in April 2015

    deacetylase (HDAC) inhibitor in all oncological indications, in particular hepatocellular carcinoma in Asia Pacific (excluding Japan).

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics